Envisioning life-changing therapies for neurodegenerative and other diseases
Our approach
Eikonizo is developing disease-modifying therapies by creating brain penetrant and peripheral small molecules to improve the lives of people impacted by neurodegenerative, cardiorenal and other diseases.
Our Programs
Our Programs
Dual Mechanism
Dual Mechanism
Supporting Literature
Supporting Literature
Therapeutic Development
Eikonizo’s unique approach to HDAC6 inhibition is designed to synergistically target the dual mechanisms of intracellular transport and proteostasis (protein homeostasis), two key drivers of neurodegenerative and cardiorenal disease biology.
Inhibiting HDAC6 in the brain and peripheral nervous system will preserve axonal transport (intracellular transport in the axons of nerve cells) and reduce aberrant protein aggregation which together may slow or stop the progression of neurodegenerative disease.
HDAC6 inhibition may also impact the course of peripheral indications such as cardiorenal disease by improving both intracellular transport and proteostasis or autophagy defects in kidney, cardiac and other cells.
These dual mechanisms also improve other common pathological disease processes including chronic inflammation, mitochondrial dysfunction and oxidative stress leading to overall improvements in cellular health and function.